Venous thrombosis in the elderly: Pathogenesis, diagnosis, treatment and follow-up;La trombosi venosa profonda età geriatrica: Patogenesi, diagnosi, trattamento e follow-up

Giornale di Gerontologia

Volumn 51, Issue 4, 2003, Pages 212-218

  Turchetti, Vera ^a   Bellini, M A ^a   Richichi, M G ^a   Boschi, L ^a   Postorino, G ^a   Naddeo, S ^a   Trabalzini, L ^a   Guerrini, M ^a   Forconi, S ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

Deep venous thrombosis; Geriatrics; Pulmonary embolism

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN III; D DIMER; HEPARIN; PHOSPHOLIPID ANTIBODY; PROTHROMBIN COMPLEX;

ADOLESCENT; ADULT; AGED; ANTITHROMBIN III DEFICIENCY; ARM DISEASE; ARTICLE; BLEEDING; CEREBROVASCULAR DISEASE; CLINICAL EXAMINATION; COLOR ULTRASOUND FLOWMETRY; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; ECCHYMOSIS; FEMALE; FOLLOW UP; FRACTURE; GENERAL SURGERY; GINGIVA BLEEDING; HEART FAILURE; HEMATURIA; HUMAN; IDIOPATHIC DISEASE; IMMOBILIZATION; LEG THROMBOSIS; LIVER HEMORRHAGE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; NEOPLASM; OCCLUSIVE CEREBROVASCULAR DISEASE; ORTHOPEDIC SURGERY; PATHOGENESIS; PROTHROMBIN DEFICIENCY; PRURITUS; RETINA VEIN OCCLUSION; RISK FACTOR; SCHOOL CHILD; THROMBOCYTOPENIA; THROMBOSIS;

LAMPROCAPNOS SPECTABILIS;

EID: 0344307644     PISSN: 00170305     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Hansson PO, Werlin L, Tibblin G, Eriksson H. Deep vein thrombosis and pulmunary embolism in the general population. Arch Intern Med 1997;157:1665-70.
2. Anderson FA, Brownwell Wheeler H, Goldberg RJ, et al. A population based perspective of the hospital incidence and case-fatality rate of deep vein thrombosis and pulmonary embolism. Arch Intern Med 1991;151:933-8.
3. Lensing AW, Prandoni P, Prins MH, Buller HR. Deep-vein thrombosis. Lancet 1999;353:479-85.
4. Martinelli I, Cattaneo M, Panzeri D, Taioli E, Mannucci PM. Risk factors for deep venous thrombosis of the upper extremities. Ann Intern Med 1997;126:707-11.
5. Prandoni P, Polistena P, Bernardi E, Cogo A, Casara D, Verlato F, et al. Upper-extremity deep vein thrombosis. Risk factors, diagnosis, and complications. Arch Intern Med 1997;157:57-62.
6. De Stefano V, Leone G, Barbui T, Finazzi G, Rodighiero F, Castman G, et al. Congenital deficiency of anthitrombin III, protein C, protein S: analysis of 160 cases. Thromb Haemost 1991;65:1044.
7. Heit JA, Silverstein MD, Petterson TM, O'Fallon WM, Melton LJ 3rd. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000;160:809-15.
8. Kroegel C, Reissig A. Principle mechanisms underlying venous thromboembolism: epidemiology, risk factors, pathophysiology and pathogenesis. Respiration 2003;70:7-30
9. Anderson FA, Brownwell Wheeler H, Goldberg RJ, et al. A population based perspective of the hospital incidence and case-fatality rate of deep vein thrombosis and pulmonary embolism. Arch Intern Med 1991;151:933-8.
10. Rosendaal FR. Risk factors for venous thrombosis: prevalence, risk and interaction. Semin Haematol 1997;34:171-87.
11. O'Donnell M, Weitz JI. Thromboprophylaxis in surgical patients. Can J Surg 2003;46:129-35.
12. Agnelli G, Sonaglia F. Prevention of venous thromboembolism in high risk patients. Haematologica 1997; 82(4): 496-502.
13. Montgomery KD, Potter HG, Helfet DL. The detection and management of proximal deep venous thrombosis in patients with acute acetabular fractures: a follow-up report. J Orthop Trauma 1997;11:330-336.
14. Cupitt JM. Prophylaxis against thromboembolism in patients with traumatic brain injury: a survey of UK practice. Anaesthesia 2001;56:780-5.
15. Prandoni P, Lensing AW, Cogo A, Cuppini S, Villalta S, Carta M, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996;125:1-7.
16. Michota FA. Venous thromboembolism prophylaxis in the medically ill patient. Clin Chest Med 2003;24:93-101.
17. Turpie AG. Thrombosis prophylaxis in the acutely ill medical patient insights from the prophylaxis in MEDical patients with ENOXaparin (MEDENOX) trial. Am J Cardiol 2000;86:48M-52M.
18. Gomes MP, Deitcher SR. Diagnosis of venous thromboembolic disease in cancer patients. Oncology (Huntingt) 2003;17:126-35,139; discussion 139-44.
19. Lee AY, Levine MN. Management of venous thromboembolism in cancer patients. Oncology 2000;14:409-17
20. Caputo F, Musardo G, Savini P, Balducci G, Marchi G, Corbelli C, et al. Occult colon cancer in a patient with an unexplained episode of pulmonary embolism. Hepatogastroenterology 2000;47:165-7.
21. Reus S, Lopez Azkarreta I, Murcia J, Manso MI. Venous thromboembolism in patients with previous cancer: a marker of tumor? Med Clin 2003;120:156.
22. Zannolli R, Mazzei MA, Sacco P, Turchetti V, Amato T, Battistini S, et al. Posterior knee as the primary symptom of a small non-occlusive venous clot. Arch Dis Child 2003;88:1-2.
23. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ. Trend in thee incidence of deep vein thrombosis and pulmunary embolism. A 25-year population-based study. Arch Intern Med 1998;158:585-94.
24. Wells PS, Anderson DR, Bormanis J, Guy F, Mitchell M, Gray L, et al. Value of assessment of pretest probability of deep-vein thrombosis in clinical management. Lancet 1997;350:1795-8.
25. Bernardi E, Prandoni P, Lensing AW, Agnelli G, Guazzaloca G, Scannapieco G, et al. D-dimer testing as an adjunct to ultrasuonography in patients with clinically suspected deep vein thrombosis: prospective cohort study. The multicentre Italian D-dimer ultrasound study investigators group. BMJ 1998;317:1037-40.
26. Kollef MH, Zahid M, Eisenberg PR. Predictive value of a rapid semiquantitative D-dimer assay in critically ill patients with suspected venous thromboembolic disease. Crit Care Med 2000;28:583-4.
27. Palareti G, Legnani C, Cosmi B, Guazzaloca G, Pancani C, Coccheri S. Risk of venous thromboembolism recurrence: high negative predictive value of D-dimer performed after oral anticoagulation is stopped. Thromb Haemost 2002;87:7-12.
28. Kearon C, Ginsberg JS, Hirsh J. The role of venous ultrasuonography in the diagnosis of suspected deep venous thrombosis and pulmonary embolism. Ann Intern Med 1998;129:1044-9.
29. Perrier A, Desmarais S, Miron MJ, de Moerloose P, Lepage R, Slosman D, et al. Non-invasive diagnosis of venous thromboembolism in outpatients. Lancet 1999;353:190-5.
30. Hull RD, Raskob GE, Rosenbloom D. Optimal therapeutic level of heparin therapy in patients with venous thrombosis. Arch Intern Med 1992;152:1589-95.
31. Albada J, Nieuwenhuis HK, Sixma JJ. Treatment of acute venous thromboembolism with low molecular weight heparin (Fragmin). Results of a double-blind randomized study. Circulation 1989;80:935-40.
32. Prandoni P, Lensing AWA, Butler HR. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992;339:441-5.
33. Linee guida delta SISET per la diagnosi, profilassi e terapia del tromboembolismo venoso: XVI Congress of the Italian Society of Hemostasis and Thrombosis, Milano 2000.
34. Prandoni P. Heparins and venous thromboembolism: current practice and future directions. Thromb Haemost. 2001;86:488-98.
35. Tapson VF. The evolution and impact of the American College of Chest Physicians consensus statement on antithrombotic therapy. Clin Chest Med 2003;24:139-51.
36. Ruiz-Irastorza G, Khamashta MA, Hunt BJ, Escudero A, Cuadrado MJ, Hughes GR. Bleeding and recurrent thrombosis in definite antiphospholipid syndrome: analysis of a series of 66 patients treated with oral anticoagulation to a target international normalized ratio of 3.5. Arch Intern Med 2002;162:1164-9.
37. Prandoni P. Terapia e prevenzione delta malattia tromboembolica venosa. Padova: Ed. Piccin 2000.
38. Sutherland DE, Weitz IC, Liebman HA. Thromboembolic complications of cancer: epidemiology, pathogenesis, diagnosis, and treatment. Am J Hematol 2003;72:43-52. R
39. Research Committee of the British Thoraci Society. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Lancet 1992;340:873-6.
40. Levine MN, Hirsh J, Gent M, Turpie AG, Weitz J, Ginsberg J, et al. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Tromb Haemost 1995;74:606-11.
41. Schulman S, Granqvist S, Holmostrom M, Carlsson A, Lindmarker P, Nicol P, et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. N Engl J Med 1997;336:393-8.
42. Debray M, Pautas E, Couturier P, Franco A, Siguret V. Oral anticoagulants in the elderly Rev Med Interne 2003;24:107-17.
43. Tufano A, Cerbone AM, Di Minno G. The use of antithrombotic drugs in older people. Minerva Med 2002;93:13-26.
44. Kyrle PA, Eichinger S. The risk of recurrent venous thromboembolism. Vasa 2002;31:163-6.
45. Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective, collaborative study (ISCOAT). Lancet 1996;348:423-8.
46. Prandoni P, Lensing AW, Piccioli A, Bernardi E, Simioni P, Girolami B, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002;100:3484-8.
47. Tormene D, Simioni P, Prandoni P, Franz F, Zerbinati P, Tognin G, et al. The incidence of venous thromboembolism in thrombophilic children: a prospective cohort study. Blood 2002;100:2403-5.
48. Girolami A, Tormene D, Simioni P, Zanon E. Long-term use of oral contraceptive therapy in women with the prothrombin 20210 G-A polymorphism without thrombotic complications: a study of 13 women (12 heterozygotes and 1 homozygote). Thromb Res 2001;102:205-10.
49. Heit JA. Risk factors for venous thromboembolism. Clin Chest Med 2003;24:1-12.
50. Pasquier E, Amiral J, de Saint Martin L, Mottier D. A cross sectional study of antiphospholipid-protein antibodies in patients with venous thromboembolism. Thromb Haemost 2001;86:538-42.
51. Perry SL, Ortel TL. Clinical and laboratory evaluation of thrombophilia. Clin Chest Med 2003;24:153-70.
52. Hayashida M, Yamada H, Yamazaki S, Nomura H, Yoshimura K, Kitahara O, et al. Intern Med 2003;42:268-72.
53. den Heijer M, Koster T, Blom HJ, et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996;334:759-62.
54. Maraglione M, D'Andrea G, Colaizzo D, Cappucci G, Del Popolo A, Brancaccio V, et al. Coexintence of factor V Leiden And Factor II A20210 mutations and recurrent venous thromboembolism. Thromb Haemost 1999;82:1583-7.
55. Pasquier E, Amiral J, de Saint Martin L, Mottier D. A cross sectional study of antiphospholipid-protein antibodies in patients with venous thromboembolism. Thromb Haemost 2001;86:538-42.
56. Agnelli G, Prandoni P, Santamaria MG, Bagatella P, Iorio A, Bazzan M, et al. Warfarin Optimal Duration Italian Trial Investigators. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. N Engl J Med 2001;345:165-9.
57. Martinelli I, Sacchi E, Landi G, Taioli E, Duca F, Mannucci PM. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med 1998;338:1840-1.
58. Prandoni P, Lensing AW, Prins MH, Bernardi E, Marchiori A, Bagatella P, et al. Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med 2002;137:955-60.
59. Prandoni P, Bernardi E, Bagatella P, Piccioli A, Marchiori A. The optimal treatment of venous thrombosis: current status and future perspectives. Clin Lab 2001;47:151-4.
60. Qari M, Abdel-Razeq H, Alzeer A, Alizadeh H, Kristensen J, al-Sayegh F, et al. Recent advances in the diagnosis and treatment of deep vein thrombosis: a regional consensus. Curr Opin Investig Drugs 2003;4:309-15.
61. Carraro P. European Communities Confederation of Clinical Chemistry and Laboratory Medicine, Working Group on Guidelines for Investigation of Disease. Guidelines for the laboratory investigation of inherited thrombophilias. Recommendations for the first level clinical laboratories. Clin Chem Lab Med 2003;41:382-91.